Cargando…

Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review

Esophageal cancer (EC) has the seventh highest incidence and the sixth highest mortality rate of any type of cancer worldwide. In China, esophageal squamous cell carcinoma (ESCC) accounts for more than 95% of EC patients. The main treatment for EC patients is surgery and/or chemoradiotherapy (CRT)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wencheng, Wang, Ping, Pang, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576075/ https://www.ncbi.nlm.nih.gov/pubmed/33241042 http://dx.doi.org/10.21037/atm-20-4625

Ejemplares similares

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy
por: Liao, Xiu-Yong, et al.
Publicado: (2019)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Prognostic values of the gross volume of metastatic lymph nodes in patients with esophageal squamous cell carcinoma treated with definitive concurrent chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2022)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
por: Stern, Peter L., et al.
Publicado: (2021)

Induction of PD-L1 expression by epidermal growth factor receptor–mediated signaling in esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2017)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors
por: Samnani, Sunil, et al.
Publicado: (2023)

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy
por: Er, Puchun, et al.
Publicado: (2020)

Chemoradiotherapy-Induced CD4(+) and CD8(+) T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma
por: Chen, Xi, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
por: Nunes Filho, Paulo, et al.
Publicado: (2023)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Prognostic value of supraclavicular nodes and upper abdominal nodes metastasis after definitive chemoradiotherapy for patients with thoracic esophageal squamous cell carcinoma
por: Li, Xue, et al.
Publicado: (2017)

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
por: Bossi, Paolo, et al.
Publicado: (2021)

Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma
por: Xiao, Linlin, et al.
Publicado: (2022)

Programmed death‐ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor
por: Zhang, Wencheng, et al.
Publicado: (2017)

Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma
por: Chen, Xi, et al.
Publicado: (2020)

Role of clip markers placed by endoscopic ultrasonography in contouring gross tumor volume for thoracic esophageal squamous cell carcinoma: one prospective study
por: Guan, Yong, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
por: Zhao, Jing-Jing, et al.
Publicado: (2018)

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
por: Wu, Xianbin, et al.
Publicado: (2021)

Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Park, Jong Chul, et al.
Publicado: (2022)

Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma
por: Du, Qingwu, et al.
Publicado: (2023)

A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy
por: Zhang, Tian, et al.
Publicado: (2022)

Correction: Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma
por: Du, Qingwu, et al.
Publicado: (2023)

Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
por: Wu, Xiaobin, et al.
Publicado: (2021)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

Esophageal carcinoma cuniculatum: a narrative review to understand this rare and commonly misdiagnosed variant of well-differentiated esophageal squamous cell carcinoma
por: Enofe, Ikponmwosa, et al.
Publicado: (2023)

The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review
por: Wang, Dan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review
por: Kujan, Omar, et al.
Publicado: (2020)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade
por: Yan, Cihui, et al.
Publicado: (2022)

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
por: Profili, Nicia I., et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
por: Chen, Ning, et al.
Publicado: (2023)

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
por: Viscardi, Giuseppe, et al.
Publicado: (2022)

Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases
por: Moskalenko, Marina, et al.
Publicado: (2021)

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: Ma, Yue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jjlu0b6mq7q1gusp8iobm0e685